TEL. 06-6210-8413

〒565-0871 大阪府吹田市山田丘2-2(0803B)




  • 2017年

  1. Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, Nonomura N, Wada H.Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules. Cancer Immunol Immunother.2017 Oct 3.

  2. Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. J Immunother. 2017 Mar 23. doi: 10.1097/CJI.0000000000000162. [Epub ahead of print]

  3.  Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, Takiguchi S, Nishikawa H, Sato E, Sakaguchi S, Mori M, Doki Y, Wada H. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017 Feb 1;140(3):686-695. doi: 10.1002/ijc.30475. Epub 2016 Oct 27.

  4.  コラム先人の足跡 「グランビーのマウスウーマン、ラスロップ」和田 尚、中山睿一 がん免疫療法 Vol.1 No.2 p.80-1, 2017

  5.  アジュバント入りがんワクチンの開発 岩堀幸太、和田 尚 バイオインダストリー 34 (9) 2017 53-58  Sep.17

  6.  Tregを標的としたがん免疫療法 浦川真哉, 土岐祐一郎, 小島隆嗣, 西川博嘉, 垣見
    和宏, 岡三喜男  中山睿一, 石田高司,飯田真介,鈴木進, 上田龍三, 和田 尚 腫瘍内科、20(2):137-142、2017

  7.  「次世代アジュバント開発のためのメカニズム解明と安全性評価」 監修 石井 健   シーエムシー出版発行 2017年3月 第4章 前臨床・臨床事例 1 アジュバント入りがんワクチンの開発1 岩堀幸太、和田 尚 251-255

  8.  カレントテラピーCurrent Therapy 2017 Vol.35 No.2 p22-26 免疫チェックポイント阻害療法における制御性T細胞の役割 岩堀幸太・和田 尚

  9.  岩堀 幸太, 和田 尚  がん免疫療法の効果予測診断法      ファルマシア Vol. 53(2017) No. 1 p.45-48

  10.  コラム先人の足跡 「ウイリアム・コーリー」和田 尚、中山睿一 がん免疫療法 Vol.1 No.1 p.62-3, 2017

  • 2016年

1.      Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Nature Medicine 22, 679–684 (2016)

2.      Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Cancer Sci. 2016 Mar 25. doi: 10.1111/cas.12938.

3.      Liver failures from ultra-short bowel syndrome on the intestinal transplant waiting list: A retrospective study. Noguchi Yuki. Transplantation Proceedings

4.      T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, Szoor A, Bonifant CL, Gerken C, Cooper LJ, Song XT, Gottschalk S. Sci Rep. 6:27130, 2016

5.      CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. Mol Ther. 24(9):1615-26, 2016.

6.      Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database. Higashiguchi M, Nagatomo I, Kijima T, Morimura O, Miyake K, Minami T, Koyama S, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A. FEBS Lett. 590(23):4275-4286, 2016.

7.      腫瘍免疫学とがん免疫療法の歴史  和田 尚、中山睿一 実験医学増刊 Vol.34 No.12 1872-1877 2016

8.      CCR4抗体を用いた制御性T細胞除去がん免疫療法  武岡奉均和田 尚 臨床免疫・アレルギー科 Vol65 545-549 2016

9.      消化器がんにおける免疫チェックポイントを標的とした治療戦略  武岡奉均和田 尚 p.160-165 次世代のがん治療薬・診断のための研究開発  技術情報協会 20162月発刊


1.      Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Clin Cancer Res. 21(19):4327-36, 2015.

2.      Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Kawashima A, Berman DM, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Int J Urol. 22(2):163-70, 2015.

3.      R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy. Nagahara A, Uemura M, Kawashima A, Ujike T, Fujita K, Miyagawa Y, Nonomura N. Int J Clin Oncol. 2015 in printing.

4.      High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. Yoshioka Y, Suzuki O, Isohashi F, Seo Y, Okubo H, Yamaguchi H, Oda M, Otani Y, Sumida I, Uemura M, Fujita K, Nagahara A, Ujike T, Kawashima A, Yoshida K, Yamazaki H, Nonomura N, Ogawa K. Int J Radiat Oncol Biol Phys. Jun 3: S0360-3016(15)00606-9, 2015.

5.      Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Mol Ther. 2015 Jan;23(1):171-8.

6.      がん免疫療法とは 1)がん免疫療法の考え方。 岩堀幸太、和田 尚 臨床腫瘍プラクティス vol.11 No.4 p.273-276  2015

7.      PD-1抗体の泌尿器科疾患, 消化器疾患への応用。和田尚 最新医学  70(3):  421 -427 2015

  • 2014年

1.Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients. Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. Vaccine. 32(8):957-64, 2014.

2.Microvessel area of immature vessels is a prognostic factor in renal cell carcinoma. Sato M, Nakai Y, Nakata W, Yoshida T, Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H, Nonomura N. Int J Urol. 21(2):130-4, 2014.

3.Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. J Immunother. 37(2):84-92, 2014.

4.Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers. Matsuzaki S, Serada S, Morimoto A, Ueda Y, Yoshino K, Kimura T, Naka T. Expert Opin Ther Targets. 18(4):403-14, 2014.

5.Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T. Int J Cancer. 134(8):1796-809, 2014.

6.Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M, Kimura T, Kobayashi E, Matsuzaki S, Egawa-Takata T, Sawada K, Tsutsui T, Kimura T. Anticancer Res. 34(7): 3589-95, 2014

7.Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Morimoto A, Ueda Y, Egawa-Takata T, Yagi A, Terai Y, Ohmichi M, Ichimura T, Sumi T, Murata H, Kanzaki H, Nakai H, Mandai M, Yoshino K, Fujita M, Kimura T, Saito J, Sobue T, Nishikawa N, Sekine M, Enomoto T, Horikoshi Y, Takagi T. Int J Clin Oncol. In press. 2014 Jul 9

9.Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T, Naka T. Oncotarget. 5(17):7776-87, 2014.

10.Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: A population-based study. Kawashima A, Berman DM, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Int J Urol. 2014 in press.

11.High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. Vaccine. 32(45):5901-7, 2014.

1.抑制性T細胞の同定と機能評価。長瀬博次、西塔拓郎、和田 尚、西川博嘉。Surgery Frontier 21(3): 70-75, 2014

2.XIV 特論 胃癌に対する免疫療法。和田 尚、土岐祐一郎。最新胃癌学 -基礎と臨床の最新研究動向-。日本臨床 72巻増刊号1 p735-739


1. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T. Int J Cancer.132(2):472-84, 2013.

2. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T. Int J Cancer. 132(2):459-71, 2013.

3.Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T. Int J Cancer.,132(2): 472-84, 2013.

4.WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H, Kimura T.  J Cancer Res Clin.139(3):457-63, 2013.

5. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, Hirao T, Shibata K, Makari Y, Iijima S, Nishikawa H, Jungbluth AA, Nakamura Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Br J Cancer. 108(5):1119-25, 2013.

6.Indazole-based potent and cell-active Mps1 kinase inhibitors: Rational design from pan-kinase inhibitor anthrapyrazolone (SP600125)  Kusakabe K-I, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue, M, Iguchi, M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai, H, Nakamura Y.  Journal of Medicinal Chemistry. 56 (11), 4343-4356, 2013.

8.EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renalcarcinoma, and its level predicts patient outcome. Sato M, Nakata W, Yoshida T, Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H, Nonomura N. Plos One.8(9), 2013.

7. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer. Hatano K, Nishimura K, Nakai Y, Yoshida T, Sato M, Kawashima A, Mukai M, Nagahara A, Uemura M, Oka D, Nakayama M, Takayama H, Shimizu K, Meguro N, Tanigawa T, Yamaguchi S, Tsujimura A, Nonomura N.                    Int J Clin Oncol. 18(4):704-10, 2013.

9.Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. J Transl Med. 11:246, 2013.

10. Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A, Kishimoto T, Naka T. Cancer Sci. 104(11):1483-91, 2013

1.RECISTirResponse Criteria. Mogamulizumabの効果判定。和田 尚、西塔拓郎、長瀬博次、土岐祐一郎。腫瘍内科 vol.12 No.4, 394-400  2013

2.2項 がんワクチン タンパクと長鎖ペプチド。和田 尚、中山睿一。ワクチン開発における最新動向  ~規制動向・安全性評価・品質管理・アジュバント・開発事例~    情報機構  2013

3.免疫バイオマーカーと抗腫瘍効果。和田 尚、中山睿一。実験医学 「腫瘍免疫学とがん免疫療法」31122028-20322013

4.癌患者における免疫モニタリング -評価法と国際標準化。和田 尚、中山睿一。医学の歩み 「がんの免疫制御研究と臨床の最前線2449号 871-8772013

5.腫瘍による制御性T細胞の浸潤誘導。 和田 尚、中山睿一。臨床・免疫アレルギー科 第592号 253-2582013





TEL 06-6210-8413
FAX 06-6210-8413